- Home
- WRN vs ESPR Comparison
WRN vs ESPR Comparison
Compare WRN & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WRN | ESPR |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 676.9M | 793.7M |
| IPO Year | 2006 | 2013 |
Fundamental Metrics
Financial Performance| Metric | WRN | ESPR |
|---|---|---|
| Price | $3.33 | $3.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.88 | ★ $7.20 |
| AVG Volume (30 Days) | 2.0M | ★ 2.9M |
| Earning Date | 01-01-0001 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 86.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $332,314,000.00 |
| Revenue This Year | N/A | $27.35 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 185.66 |
| 52 Week Low | $0.90 | $0.73 |
| 52 Week High | $4.26 | $4.18 |
Technical Indicators
Market Signals| Indicator | WRN | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 51.05 | 43.62 |
| Support Level | $2.95 | $3.16 |
| Resistance Level | $4.26 | $3.41 |
| Average True Range (ATR) | 0.20 | 0.14 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 69.83 | 5.75 |
Price Performance
Historical ComparisonAbout WRN Western Copper and Gold Corporation
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project).
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.